HCW BIOLOGICS INC (HCWB)
US40423R1059 - Common Stock
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023
HCWB stock results show that HCW Biologics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the fourth quarter of 202...
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
Q4 and Year End Earnings Release and Business Highlights...
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights ...
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors. ...
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW9218 is the lead product candidate of HCW Biologics Inc.
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023...
HCW Biologics director Gary Winer buys shares worth $3.3k - filing (NASDAQ:HCWB)
HCW Biologics (HCWB) director Gary Winer disclosed in an SEC filing on Friday after the bell a purchase of 1,587 shares of the company at prices ranging from $2, $2.05, and $2.08 per...
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the...
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical...
Top Buys by Top Brass: Chief Financial Officer Byam's $317.1K Bet on HCWB
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects...
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical...
HCW Biologics climbs 19% on $26.25M asset-backed development loan (NASDAQ:HCWB)
Clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and...
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 ...
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc....
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells...
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage...
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer...
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying...